Myoscience Announces the Completion of Enrollment in the Campbell Clinic Study
FREMONT, Calif. (PRWEB) October 30, 2018 -- Myoscience, Inc. announced today that it has completed enrollment in its randomized, controlled trial at the Campbell Clinic in Memphis, Tennessee. This study enrolled 125 patients and compares the effect of cryoanalgesia using the iovera° system to the standard of care for managing pain after total knee replacement surgery (TKA).
The Myoscience iovera° system is currently being used to treat chronic and perioperative knee pain. The Campbell Clinic study will demonstrate how cryoanalgesia can significantly reduce opioid consumption after TKA, and lead to improved physical function and enhanced recovery. Analysis of interim data confirms that cryoanalgesia with the iovera° system can be a preferred treatment for relieving postoperative TKA pain.
“I am very impressed with the results of this prospective randomized study thus far. The positive effect of the iovera° system has exceeded our original expectations”, stated Dr. William Mihalko, MD, Principal Investigator for this study. “Having a technology as effective as this to combat excessive opioid use after primary TKA can be a game changer for many patients. Many of us will adopt the use of the technology on a regular basis at my institution,” he added.
The company will be sharing these interim results during a sponsored symposium at the upcoming American Association of Hip and Knee Surgeons (AAHKS) annual meeting in Dallas, Texas. The symposium “Cryoanalgesia: A Path to an Opioid-Free TKA, Pre-op through Rehab,” will be held from 10 a.m. to noon on November 1.
Timothy I. Still, President and CEO of Myoscience stated, “I share Dr. Mihalko’s enthusiasm about iovera°. We look forward to sharing these interim results during the AAHKS meeting in a few days.”
For additional information, please visit http://www.iovera.com or email us directly at mediarelations(at)myoscience(dot)com.
ABOUT MYOSCIENCE
Silicon Valley, California-based Myoscience is a privately-held medical device company committed to making its platform technology, the iovera° system, the standard of care for the treatment of peripheral nerves. The iovera° treatment is powered by a patented device that enables cryoneurolysis. The ioveraº system is 510k cleared in the U.S. for the blocking of pain, the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days and general surgical use. For more information, please visit http://www.iovera.com.
© 2018 Myoscience. All rights reserved. iovera° is a trademark of Myoscience. MKT-0524 REV A
Kris Kumar, Myoscience, Inc., http://ww.iovera.com, +1 4088353854, [email protected]
Share this article